GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson’s disease animal models
Pharmacological Research · 2024
DOI: 10.1016/j.phrs.2024.107432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2024. Verfasst von Tae-Young Ha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Research Institute, Gachon University, Incheon 21565, Republic of Korea; Department of Pharmacology, College of Medicine, Gachon Univers…. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Mice, Inbred C57BL, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health and Welfare, Korea Ministry of Science and ICT, National Research Foundation of Korea.
Abstract (Originalsprache)
Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra (SN) and accumulation of intracellular α-synuclein (ɑ-syn) aggregates known as Lewy bodies and Lewy neurites. Levels of polyunsaturated fatty acids (PUFAs) have previously been shown to be reduced in the SN of PD patients. G protein-coupled receptor 40 (GPR40) serves as a receptor for PUFAs, playing a role in neurodevelopment and neurogenesis. Additionally, GPR40 has been implicated in several neuropathological conditions, such as apoptosis and inflammation, suggesting its potential as a therapeutic target in PD. In this study, we investigated the neuroprotective effects of the GPR40 agonist, TUG469 in PD models. Our results demonstrated that TUG469 reduces the neurotoxicity induced by 6-OHDA in SH-SY5Y cells. In 6-OHDA-induced PD model mice, TUG469 treatment improved motor impairment, preserved dopaminergic fibers and cell bodies in the striatum (ST) or SN, and attenuated 6-OHDA-induced microgliosis and astrogliosis in the brain. Furthermore, in a PD model involving the injection of mouse ɑ-syn fibrils into the brain (mPFFs-PD model), TUG469 treatment reduced the levels of pSer129 ɑ-syn, and decreased microgliosis and astrogliosis. Our investigation also revealed that TUG469 modulates inflammasome activation, apoptosis, and autophagy in the 6-OHDA-PD model, as evidenced by the results of RNA-seq and western blotting analyses. In summary, our findings highlight the neuroprotective effects of GPR40 agonists on dopaminergic neurons and their potential as therapeutic agents for PD. These results underscore the importance of targeting GPR40 in PD treatment, particularly in mitigating neuroinflammation and preserving neuronal integrity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Research Institute, Gachon University, Incheon 21565, Republic of Korea; Department of Pharmacology, College of Medicine, Gachon University, Incheon 21999, Republic of Korea.
- Department of Pharmacology, School of Medicine, Ajou University, Suwon, 16499, Republic of Korea; Center for Convergence Research of Neurological Disorders, Ajou University School of Medicine, Suwon, 16499, Republic of…
- Department of Health Science and Technology, Gachon Advanced Institute for Health Sciences & Technology, Gachon University, Incheon 21999, Republic of Korea.
- Neuroscience Research Institute, Gachon University, Incheon 21565, Republic of Korea; Department of Pharmacology, College of Medicine, Gachon University, Incheon 21999, Republic of Korea; Department of Health Science an…
Förderung
- Ministry of Health and Welfare
- Korea Ministry of Science and ICT
- National Research Foundation of Korea
- Korea Dementia Research Center
Zitieren
APA
Ha, T. Y., Kim, J. B., Kim, Y., Park, S. M., & Chang, K. A. (2024). GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson’s disease animal models. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107432
Vancouver
Ha TY, Kim JB, Kim Y, Park SM, Chang KA. GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson’s disease animal models. Pharmacological Research. 2024. doi:10.1016/j.phrs.2024.107432
BibTeX
@article{Ha2024,
author = {Ha, Tae-Young and Kim, Jae-Bong and Kim, Yeji and Park, Sang Myun and Chang, Keun-A},
title = {GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson’s disease animal models},
journal = {Pharmacological Research},
year = {2024},
doi = {10.1016/j.phrs.2024.107432}
}
EUVIMED